Center for Financial Professionals Names Experian to 2023 Global Fintech Leaders Report for Fourth Consecutive Year
Experian’s fraud prevention, advanced data and analytics, customer experience and credit decisioning remain key drivers…
Year: 2023
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
The settlement between Statera Biopharma, Inc. and Biostax Corp. includes an amended royalty-bearing license agreement…
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
The settlement between Statera Biopharma, Inc. and Biostax Corp. includes an amended royalty-bearing license agreement…
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT…
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT…
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader,…
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader,…
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”),…
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”),…
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once…
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once…
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity…
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity…
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…